Travis Steed
Stock Analyst at B of A Securities
(2.93)
# 1,478
Out of 4,778 analysts
84
Total ratings
46.27%
Success rate
8.02%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Initiates: Buy | $320 | $283.58 | +12.84% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $125.63 | +19.40% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $74.91 | +13.47% | 3 | Feb 26, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $278 → $279 | $228.14 | +22.30% | 7 | Feb 14, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $71.26 | +26.30% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $20.20 | +58.42% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $32.95 | +36.57% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $11.64 | +286.76% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $372.96 | -15.54% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $272.64 | +8.20% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $18.99 | -15.75% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $20.22 | +63.20% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $110.37 | +44.97% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $519.67 | -39.38% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $6.89 | +16.11% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $12.65 | +97.71% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $18.43 | +361.20% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $73.52 | +70.02% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $88.62 | +63.62% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $103.10 | -50.53% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $59.73 | +193.01% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $22.17 | +143.57% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $99.77 | -77.95% | 1 | Jul 17, 2017 |
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $283.58
Upside: +12.84%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $125.63
Upside: +19.40%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $74.91
Upside: +13.47%
Becton, Dickinson and Company
Feb 14, 2025
Maintains: Overweight
Price Target: $278 → $279
Current: $228.14
Upside: +22.30%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $71.26
Upside: +26.30%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $20.20
Upside: +58.42%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $32.95
Upside: +36.57%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $11.64
Upside: +286.76%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $372.96
Upside: -15.54%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $272.64
Upside: +8.20%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $18.99
Upside: -15.75%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $20.22
Upside: +63.20%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $110.37
Upside: +44.97%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $519.67
Upside: -39.38%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $6.89
Upside: +16.11%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $12.65
Upside: +97.71%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $18.43
Upside: +361.20%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $73.52
Upside: +70.02%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $88.62
Upside: +63.62%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $103.10
Upside: -50.53%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $59.73
Upside: +193.01%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $22.17
Upside: +143.57%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $99.77
Upside: -77.95%